UVA scientists have developed K-9, an experimental drug that reversed MS damage in mice, restoring mobility and vision. Derived from HIV and hepatitis B drugs, K-9 targets MS-related brain and spinal cord damage. Human clinical trials are needed to confirm its effectiveness and safety.

UVA scientists have developed K-9, an experimental drug that reversed MS damage in mice, restoring mobility and vision. Derived from HIV and hepatitis B drugs, K-9 targets MS-related brain and spinal cord damage. Human clinical trials are needed to confirm its effectiveness and safety.

UVA scientists have developed K-9, an experimental drug that reversed MS damage in mice, restoring mobility and vision. Derived from HIV and hepatitis B drugs, K-9 targets MS-related brain and spinal cord damage. Human clinical trials are needed to confirm its effectiveness and safety.

UVA scientists have developed K-9, an experimental drug that reversed MS damage in mice, restoring mobility and vision. Derived from HIV and hepatitis B drugs, K-9 targets MS-related brain and spinal cord damage. Human clinical trials are needed to confirm its effectiveness and safety.

UVA scientists have developed K-9, an experimental drug that reversed MS damage in mice, restoring mobility and vision. Derived from HIV and hepatitis B drugs, K-9 targets MS-related brain and spinal cord damage. Human clinical trials are needed to confirm its effectiveness and safety.

UVA scientists have developed K-9, an experimental drug that reversed MS damage in mice, restoring mobility and vision. Derived from HIV and hepatitis B drugs, K-9 targets MS-related brain and spinal cord damage. Human clinical trials are needed to confirm its effectiveness and safety.

UVA scientists have developed K-9, an experimental drug that reversed MS damage in mice, restoring mobility and vision. Derived from HIV and hepatitis B drugs, K-9 targets MS-related brain and spinal cord damage. Human clinical trials are needed to confirm its effectiveness and safety.